BR112021016348A2 - Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira - Google Patents

Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira

Info

Publication number
BR112021016348A2
BR112021016348A2 BR112021016348A BR112021016348A BR112021016348A2 BR 112021016348 A2 BR112021016348 A2 BR 112021016348A2 BR 112021016348 A BR112021016348 A BR 112021016348A BR 112021016348 A BR112021016348 A BR 112021016348A BR 112021016348 A2 BR112021016348 A2 BR 112021016348A2
Authority
BR
Brazil
Prior art keywords
protein
plant
fusion protein
ligand
polynucleotide encoding
Prior art date
Application number
BR112021016348A
Other languages
English (en)
Portuguese (pt)
Inventor
Houry Max
MAGY Bertrand
Original Assignee
Atb Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atb Therapeutics filed Critical Atb Therapeutics
Publication of BR112021016348A2 publication Critical patent/BR112021016348A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112021016348A 2019-02-18 2020-02-18 Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira BR112021016348A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157839 2019-02-18
PCT/EP2020/054263 WO2020169620A1 (en) 2019-02-18 2020-02-18 Method of producing a binder-toxin fusion protein in a plant cell or a whole plant

Publications (1)

Publication Number Publication Date
BR112021016348A2 true BR112021016348A2 (pt) 2021-11-23

Family

ID=65717705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016348A BR112021016348A2 (pt) 2019-02-18 2020-02-18 Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira

Country Status (11)

Country Link
US (1) US20220090113A1 (https=)
EP (2) EP4733324A2 (https=)
JP (2) JP7150999B2 (https=)
KR (1) KR102398485B1 (https=)
CN (2) CN115925972A (https=)
BR (1) BR112021016348A2 (https=)
CA (1) CA3128793C (https=)
ES (1) ES3055338T3 (https=)
IL (1) IL285719B (https=)
WO (1) WO2020169620A1 (https=)
ZA (1) ZA202105654B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925972A (zh) * 2019-02-18 2023-04-07 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
CN115768897B (zh) * 2020-05-28 2026-03-27 中外制药株式会社 改进的颗粒酶b变体
JP7818834B2 (ja) 2020-08-17 2026-02-24 エーティービー セラピューティクス リボトキシンまたはＲＮＡｓｅを含む組換え免疫毒素
EP4328243A4 (en) * 2021-04-20 2025-05-21 Korea University Research and Business Foundation Asymmetric antibody with improved cytotoxicity against cancer cell
IL314969A (en) 2022-02-17 2024-10-01 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
CN114605556B (zh) * 2022-03-10 2023-04-14 南开大学 一种增强植物根系募集功能细菌的融合蛋白及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6140075A (en) 1994-07-25 2000-10-31 Monsanto Company Method for producing antibodies and protein toxins in plant cells
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
WO2003007889A2 (en) * 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
JP2006507800A (ja) 2002-06-07 2006-03-09 ラージ・スケール・バイオロジー・コーポレイション 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CA2705289A1 (en) * 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US9586996B2 (en) * 2010-04-30 2017-03-07 Esperance Pharmaceuticals, Inc. Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
US20130145502A1 (en) 2010-06-09 2013-06-06 Pioneer Hi-Bred International, Inc. Regulatory sequences for modulating transgene expression in plants
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
WO2016187585A1 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Deimmunized linker and methods of use
CN105753986B (zh) * 2016-04-24 2019-12-10 赵磊 一类抗cd20靶向抗体及用途
CN115925972A (zh) * 2019-02-18 2023-04-07 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法

Also Published As

Publication number Publication date
CA3128793C (en) 2023-02-28
EP3927831B1 (en) 2025-11-12
US20220090113A1 (en) 2022-03-24
KR102398485B1 (ko) 2022-05-16
ZA202105654B (en) 2023-04-26
WO2020169620A1 (en) 2020-08-27
CA3128793A1 (en) 2020-08-27
EP3927831C0 (en) 2025-11-12
KR20210120051A (ko) 2021-10-06
ES3055338T3 (en) 2026-02-11
CN113728107B (zh) 2022-06-24
EP4733324A2 (en) 2026-04-29
JP2022176933A (ja) 2022-11-30
EP3927831A1 (en) 2021-12-29
JP2022518614A (ja) 2022-03-15
JP7728587B2 (ja) 2025-08-25
CN115925972A (zh) 2023-04-07
IL285719B (en) 2022-07-01
IL285719A (en) 2021-10-31
CN113728107A (zh) 2021-11-30
JP7150999B2 (ja) 2022-10-11

Similar Documents

Publication Publication Date Title
BR112021016348A2 (pt) Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira
Reyt et al. Two chemically distinct root lignin barriers control solute and water balance
Eskelinen et al. Links between plant community composition, soil organic matter quality and microbial communities in contrasting tundra habitats
Xie et al. Phenolic acid-induced phase separation and translation inhibition mediate plant interspecific competition
Kosmacz et al. Protein and metabolite composition of Arabidopsis stress granules
Huang et al. Lower incidence and severity of tomato virus in elevated CO2 is accompanied by modulated plant induced defence in tomato
Tausta et al. Developmental dynamics of Kranz cell transcriptional specificity in maize leaf reveals early onset of C4-related processes
Ghatak et al. Proteomics survey of Solanaceae family: current status and challenges ahead
BRPI0620803B8 (pt) anticorpo isolado ou fragmento de anticorpo anti-her-3, seu processo de preparação, composição farmacêutica e kit compreendendo o mesmo, molécula de ácido nucléico codificando o referido anticorpo, vetor compreendendo o mesmo, microrganismo transgênico, bem como método para diagnosticar uma doença associada a her-3
Ikeda et al. Mass outbreak of food poisoning disease caused by small amounts of staphylococcal enterotoxins A and H
Suorsa et al. Light acclimation involves dynamic re‐organization of the pigment–protein megacomplexes in non‐appressed thylakoid domains
CY1123419T1 (el) Αντιδραστηρια sirp-αλφα υψηλης συγγενειας
Ge et al. iTRAQ‐based quantitative proteomic analysis reveals new metabolic pathways of wheat seedling growth under hydrogen peroxide stress
Chen et al. Stable megadalton TOC–TIC supercomplexes as major mediators of protein import into chloroplasts
BR112012007821A2 (pt) polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos
Albulescu et al. A decoy-receptor approach using nicotinic acetylcholine receptor mimics reveals their potential as novel therapeutics against neurotoxic snakebite
Tacheny et al. Mass spectrometry-based identification of proteins interacting with nucleic acids
Zhou et al. Quantitative iTRAQ proteomics revealed possible roles for antioxidant proteins in sorghum aluminum tolerance
WO2011073214A3 (en) A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
BR112013004579A2 (pt) proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9
BRPI0817447A2 (pt) Molécula de ácido nucleico isolado, planta transformada, semente, célula hospedeira não-humana, métodos para aumentar a resistência de uma planta a pelo menos um patógeno de planta, para expressar um gene de interesse em uma planta ou célula de planta, para expressar genes em alto nível em uma planta ou célula de planta e para causar morte celular em uma parte da planta de interesse, e, polipeptídeo isolado.
GB2464888A (en) Compositions and methods for detecting and modulating cell death by a translation regulated gene expression system
BRPI0813242A2 (pt) Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
AR066406A1 (es) Defensina de planta quimerica
WO2012085069A3 (en) Detection of a polypeptide dimer by a bivalent binding agent